Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Department of Medicine, McMaster University
-
-
Quebec
-
Sainte-Foy (Quebec City), Quebec, Canada, G1V 4G5
- Centre de cardiology et de pneumologie de l'Universite Laval
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- University of Saskatchewan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild stable allergic asthma
- Positive skin-prick test to at least one common aeroallergen
- Positive methacholine challenge
- Positive allergen-induced early- and late-phase airway bronchoconstriction
- General good health
Exclusion Criteria:
- Lung diseases other than mild allergic asthma
- History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
- Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
- Use of tobacco products within one year starting study or smoking history >10 pack years
- If female, pregnant or lactating or have positive pregnancy test at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Serial lung function tests measured up to 7 hours post-allergen challenge to assess effects on early- and late-phase asthmatic reactions
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Methacholine PC20 pre- and post-allergen challenge
|
|
Anti-inflammatory activity in airways
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Paul M O'Byrne, MD, McMaster University and AllerGen NCE
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IXR-201-04-142
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.